DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo


43.70 -1.29 (-2.87%)

Quote as of

company name or ticker

Recent Quotes

XON $43.70 -2.87%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $44.40
Previous Close $44.99
Daily Range $42.98 - $44.61
52-Week Range $13.13 - $50.98
Market Cap $4.6B
P/E Ratio -54.20
Dividend (Yield) $0.00 (0.0%)
Volume 962,267
Average Daily Volume 1,417,952
Current FY EPS -$0.36





News & Commentary Rss Feed

Shell/BG Merger Could Be the Start of a Major Trend in 2015

The Shell/BG Group merger may signal the beginning of a flurry of M&A activity in the oil and gas sector as commodity prices put smaller companies under pressure.

Soligenix Takes the Fast Track to Beat Inflammation, Cancer and Bio-Threats: Dr. Christopher Schaber

MedAssets: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog

Stock To Watch: Intrexon (XON) In Perilous Reversal

3 Biotech Products Intrexon Wants You to Know About

Cancer deal this, cancer deal that. Intrexon investors should pay attention to the growth potential beyond healthcare applications.

Disruptive Innovation Changing the Fight Against Cancer

After decades of false starts, new immunotherapies are achieving long-lasting remissions in patients with extremely deadly cancers. Some doctors are even daring to use the word "cure."

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

Intrexon Signs Cooperative Research and Development Agreement with the National Cancer Institute

Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog

Trade-Ideas: Intrexon (XON) Is Today's "Perilous Reversal" Stock

See More XON News...